Citrus Bergamot Supplement Guide: Cholesterol Benefits, Dosage, and Clinical Evidence (2026)

What Is Citrus Bergamot?

Citrus bergamot is a citrus fruit native to the coastal strip of Calabria in southern Italy. Its juice extract contains an unusually high concentration of polyphenolic flavonoids, particularly naringin, neoeriocitrin, and neohesperidin, that modulate cholesterol synthesis, glucose metabolism, and oxidative stress through multiple biochemical pathways.

Citrus bergamia Risso et Poit. is distinct from bergamot orange essential oil used in Earl Grey tea and aromatherapy. The supplement form uses the juice or albedo extract standardized for polyphenol content, not the aromatic peel oil. This distinction matters because the biological activity resides in the flavonoid fraction, not the volatile terpenes that give bergamot its fragrance.

What makes bergamot unique among citrus fruits is its polyphenol profile. While all citrus fruits contain flavonoids, bergamot has particularly high concentrations of three specific compounds: naringin, neoeriocitrin, and neohesperidin. These flavonoids, and their metabolites naringenin and hesperetin — interact with enzymes and receptors involved in cholesterol synthesis, lipid transport, and glucose regulation (Mollace et al., 2011).

Bergamot cultivation is geographically concentrated. Most of the world's bergamot comes from a narrow strip along the Calabrian coast in southern Italy, where specific soil and climate conditions support the fruit's unique phytochemical composition. This limited growing region contributes to bergamot's relatively high supplement cost compared to other citrus-derived ingredients.

How Does Citrus Bergamot Lower Cholesterol?

Bergamot flavonoids appear to act on more than one pathway. A bergamot polyphenol fraction inhibited HMG-CoA reductase, the enzyme statins block, and lowered total cholesterol, LDL, triglycerides and blood glucose in early human work (Mollace et al., 2011). The 2024 placebo-controlled trial also found lower oxidized LDL and higher activity of PON1, an antioxidant enzyme carried on HDL (Spina et al., 2024).

The best-documented mechanism mirrors statins: a bergamot polyphenol fraction inhibited HMG-CoA reductase activity (Mollace et al., 2011). The effect is much weaker than a prescription statin. Statins can lower LDL by 50% to 60% (Lamiquiz-Moneo et al., 2020), while bergamot lowered LDL by 7% to 12% in the placebo-controlled trials (Spina et al., 2024) (Yu et al., 2026).

A second proposed pathway is AMP-activated protein kinase (AMPK), the cell's energy sensor. AMPK activation shifts metabolism away from fat storage and toward fat burning and improves insulin sensitivity. This link comes mainly from laboratory work; in people, the clearest signal is the fall in blood glucose reported alongside lipid changes after 30 days of a bergamot polyphenol fraction (Mollace et al., 2011).

Beyond cholesterol metabolism, bergamot demonstrates antioxidant effects specifically relevant to cardiovascular risk: it reduces oxidized LDL (ox-LDL). Oxidized LDL is the form of cholesterol that triggers inflammatory responses in arterial walls and drives atherosclerotic plaque formation. The Spina et al., 2024 trial measured a statistically significant 2% reduction in ox-LDL in the bergamot group, modest but mechanistically relevant (Spina et al., 2024).

Bergamot also raised paraoxonase-1 (PON1) activity by 6.5% in the 2024 trial (Spina et al., 2024). PON1 travels on HDL particles and helps protect LDL from oxidation.

Clinical Evidence: What the Human Trials Show

Two placebo-controlled RCTs using a standardized extract that supplies 150 mg/day of flavonoids give the most reliable data. The 2024 trial in Caucasian adults found 8.8% lower total cholesterol and 11.5% lower LDL (Spina et al., 2024); the 2026 trial in East Asian adults found 7.3% and 7.0% (Yu et al., 2026). Earlier open-label studies at 500 to 1,000 mg/day reported larger and more variable changes, but without blinding they are less reliable (Lamiquiz-Moneo et al., 2020).

The strongest evidence comes from two double-blind, placebo-controlled trials that used a standardized bergamot juice extract providing 150 mg/day of flavonoids: (Spina et al., 2024) (Yu et al., 2026)

2024 Caucasian Population Trial (Spina et al.), 64 subjects with high LDL cholesterol (160–190 mg/dL) received either 150 mg/day of standardized bergamot flavonoids or placebo for four months. The bergamot group showed statistically significant reductions in total cholesterol (−8.8%, p < 0.001) and LDL-C (−11.5%, p < 0.001). HDL showed a favorable +5.5% trend. Oxidized LDL decreased by 2.0%, and the safety profile was clean, no changes in liver enzymes, kidney function, weight, or blood pressure (Spina et al., 2024).

2026 Asian Population Trial (Yu et al.), 108 East Asian adults with LDL-C of 100–159 mg/dL (a lower baseline than the Caucasian trial) received the same 150 mg/day extract or placebo for four months. Total cholesterol decreased by 7.3% and LDL-C by 7.0%. This trial confirmed that the bergamot effect is not limited to a single ethnic population, a cross-ethnic replication that strengthens the evidence base (Yu et al., 2026).

Earlier studies used a bergamot polyphenol fraction (BPF) at 500 to 1,000 mg/day. In the first large report, 30 days of BPF lowered total and LDL cholesterol, triglycerides and blood glucose in 237 patients with high blood lipids (Mollace et al., 2011). An open-label study of 77 patients then found that 1,000 mg/day of BPF lowered LDL on its own and strengthened the LDL-lowering effect of 10 mg rosuvastatin (Gliozzi et al., 2013). Neither design was blinded, so the effect sizes are less trustworthy than those of the newer RCTs.

Combining bergamot with other ingredients does not guarantee a bigger effect. A 2025 placebo-controlled trial tested a commercial blend of plant sterols, bergamot extract, artichoke leaf extract and hydroxytyrosol in adults with mild hypercholesterolaemia. It was safe, but it did not lower LDL or any other lipid or oxidative stress marker compared with placebo, and the authors raised the possibility that the ingredients interfere with each other (Stonehouse et al., 2025).

A 2020 systematic review found 12 eligible studies, and 75% of them reported significant drops in total cholesterol, triglycerides and LDL. Reported changes ranged from 12.3% to 31.3% for total cholesterol and from 7.6% to 40.8% for LDL, but the studies were heterogeneous and their quality was limited (Lamiquiz-Moneo et al., 2020). The placebo-controlled trials point to the lower end of that range.

Bergamot for Blood Sugar and Metabolic Health

Preclinical and early clinical evidence suggests that bergamot polyphenols improve insulin sensitivity and fasting glucose through AMPK activation and anti-inflammatory pathways. The lipid-lowering trials often report concurrent improvements in glycemic markers, though no large RCT has been designed specifically for diabetes outcomes.

The AMPK pathway linked to bergamot is the same pathway metformin acts on. When AMPK is active, cells take up more glucose and the liver releases less. In people, the evidence is limited to the glucose drop reported in early, uncontrolled work (Mollace et al., 2011).

The newer placebo-controlled trials were designed around lipids, not glucose (Spina et al., 2024) (Yu et al., 2026). Until a trial targets blood sugar directly, any glucose benefit should be treated as possible rather than proven.

However, no large, well-controlled RCT has been conducted with blood sugar or diabetes management as the primary endpoint. The glucose-lowering effect of bergamot should be considered a potential secondary benefit rather than a primary indication. People with type 2 diabetes using bergamot alongside antidiabetic medications should monitor blood glucose closely, as additive effects on glucose lowering are theoretically possible.

How to Take Citrus Bergamot: Dosage and Timing

The best-validated dose is 150 mg/day of standardized bergamot flavonoids (equivalent to approximately 375 mg of standardized extract). Take it with food to enhance polyphenol absorption. Effects on lipid biomarkers typically become measurable at the two-month mark and reach their maximum by four months of consistent use.

Dosing in the bergamot literature varies significantly because different products use different standardization methods:

150 mg/day standardized flavonoids — the dose validated in both the 2024 and 2026 RCTs. This corresponds to roughly 375 mg of the standardized extract, which provides 40% flavonoids by weight. This is the most evidence-based recommendation for cholesterol management.

500–1,000 mg/day of bergamot polyphenol fraction (BPF), the dose range used in earlier, less rigorous studies. Some commercial supplements use this higher dose, which may provide larger effects but has only open-label evidence to support it.

Take bergamot with a meal. The trials did not compare timing, so taking it consistently matters more than the exact time of day.

In the 2024 trial, LDL had already fallen at two months and fell further by four months (Spina et al., 2024). Two months is too early to judge your own response; plan on about four months before a follow-up lipid test.

Side Effects and Drug Interactions

Citrus bergamot extract has a favorable safety profile in clinical trials, with no significant adverse effects reported at the studied doses. The primary caution is a potential interaction with statin medications through CYP3A4 enzyme inhibition, and people taking calcium channel blockers or other CYP3A4-metabolized drugs should consult their physician before starting bergamot supplementation.

In the 2024 and 2026 RCTs, liver enzymes, kidney function markers, weight, and blood pressure remained unchanged in the bergamot groups compared to placebo. No serious adverse events were reported, and the treatment was well-tolerated throughout the four-month study periods (Spina et al., 2024) (Yu et al., 2026).

Bergamot is a citrus relative of grapefruit, and the peel contains furanocoumarins, compounds that inhibit the drug-metabolizing enzyme CYP3A4 in grapefruit juice. Standardized juice extracts contain much less, and the RCTs did not report drug interactions, but people taking CYP3A4-metabolized drugs (including atorvastatin, simvastatin and some calcium channel blockers) should check with a pharmacist first.

People already taking a statin who want to add bergamot should do so with medical supervision. In an open-label study of 77 patients, adding 1,000 mg/day of bergamot polyphenol fraction to 10 mg rosuvastatin lowered LDL more than rosuvastatin alone, but the design was not blinded (Gliozzi et al., 2013).

Who Should Consider Bergamot Supplementation?

The best candidates for bergamot are adults with mildly to moderately elevated LDL cholesterol (130–189 mg/dL) who prefer to try lifestyle and supplement interventions before or alongside medication, and statin-intolerant individuals seeking evidence-based alternatives. Bergamot is not a replacement for statins in high-risk cardiovascular patients.

Based on the current evidence, bergamot supplementation makes the most sense for:

Adults with borderline or mildly elevated LDL, if your LDL is in the 130–160 mg/dL range and your overall cardiovascular risk is low to moderate, bergamot plus dietary modifications may produce sufficient improvement to avoid or delay statin initiation.

Statin-intolerant individuals, some people prescribed statins experience muscle pain or other side effects that lead to discontinuation. For these individuals, bergamot offers a mechanistically distinct approach to cholesterol management.

As an adjunct to statin therapy, for people whose LDL does not reach target on a statin alone, adding bergamot may provide additional reduction. The open-label Gliozzi data on bergamot plus rosuvastatin supports this approach under medical supervision.

People with metabolic syndrome, the concurrent effects on lipids, glucose, and oxidative stress markers make bergamot particularly relevant for the cluster of risk factors that defines metabolic syndrome.

Who should not use bergamot as a standalone cholesterol strategy: people with very high LDL (≥190 mg/dL), established cardiovascular disease, or high 10-year ASCVD risk scores. These populations benefit from proven pharmacological interventions, primarily statins — and should not substitute supplements for evidence-based medical therapy.

Bergamot and Liver Health: NAFLD Evidence

Preclinical research shows that bergamot polyphenols stimulate lipophagy (fat-specific autophagy) in liver cells, reducing intracellular lipid accumulation, the hallmark of non-alcoholic fatty liver disease (NAFLD). A 2015 study demonstrated that bergamot polyphenol fraction (BPF) prevented NAFLD development in high-fat-diet models by stimulating lipophagy, offering a potential mechanism for liver health beyond cholesterol management (Parafati et al., 2015).

Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of the global population and is the most common chronic liver condition in Western countries. It is characterized by excessive fat accumulation in liver cells (hepatic steatosis) and is tightly linked to metabolic syndrome, insulin resistance, and dyslipidemia, the same conditions that bergamot's primary mechanisms address.

The liver is the central organ for lipid metabolism, and bergamot's AMPK activation has direct hepatic consequences. When AMPK is activated in liver cells, it suppresses de novo lipogenesis (the creation of new fat from carbohydrates), enhances fatty acid oxidation, and, critically, stimulates lipophagy, a selective form of autophagy that specifically targets and degrades intracellular lipid droplets.

Parafati and colleagues showed this in rats fed a high-fat cafeteria diet: a bergamot polyphenol fraction raised autophagy markers (LC3 and Beclin 1), increased autophagy activity inside liver fat droplets and prevented fatty liver (Parafati et al., 2015).

In a mouse model of non-alcoholic steatohepatitis, a bergamot polyphenol fraction improved liver histology, ALT and blood lipids (Musolino et al., 2020). No human trial has tested bergamot as a primary treatment for fatty liver.

For people with elevated liver enzymes or diagnosed NAFLD, bergamot supplementation alongside lifestyle modifications (dietary improvement, exercise, weight loss) represents a mechanistically sound adjunctive approach. However, bergamot is not a substitute for the primary interventions for NAFLD, which remain weight loss, dietary modification, and exercise. No clinical trial has evaluated bergamot as a primary intervention for NAFLD, the current evidence is preclinical and secondary outcome data from lipid trials.

Bergamot and Oxidative Stress Protection

Bergamot polyphenols provide cardiovascular protection beyond LDL reduction by decreasing oxidized LDL (ox-LDL) and increasing paraoxonase-1 (PON1) activity, an HDL-associated enzyme that protects LDL from oxidative modification. The 2024 RCT measured a significant reduction in ox-LDL alongside the cholesterol improvements, addressing the qualitative aspect of cardiovascular risk, not just the quantitative (Spina et al., 2024).

LDL cholesterol becomes dangerous when it is oxidized. Native (non-oxidized) LDL particles pass through arterial walls relatively harmlessly. Oxidized LDL particles trigger inflammatory responses, recruit macrophages, and initiate the formation of atherosclerotic plaques. This is why ox-LDL is considered a more direct predictor of cardiovascular events than total LDL in some analyses.

Bergamot flavonoids — particularly naringin and neoeriocitrin, act as direct antioxidants that scavenge free radicals capable of oxidizing LDL particles. They also increase the activity of paraoxonase-1 (PON1), an enzyme carried on HDL particles that hydrolyzes oxidized phospholipids on LDL surfaces. Higher PON1 activity means more efficient clearance of early oxidative damage before it triggers inflammatory signaling.

The Spina et al., 2024 trial measured a 2.0% reduction in ox-LDL in the bergamot group compared to placebo, a statistically significant finding. While this percentage appears small, it reflects a meaningful shift in the oxidative balance of circulating lipoproteins. In the context of the concurrent LDL reduction (11.5%), the combined effect is a smaller amount of total LDL that is also less oxidized, a qualitative improvement on top of the quantitative one.

In a 2018 animal study, a bergamot polyphenolic fraction limited the early heart damage caused by the chemotherapy drug doxorubicin by reducing oxidative stress, restoring protective autophagy and reducing heart muscle cell death (Carresi et al., 2018).

Bergamot Supplement Quality: What to Look For

The clinical evidence is specific to standardized flavonoid extracts from Citrus bergamia juice or albedo, not essential oil, not peel extract, and not unstandardized powder. Look for products specifying total flavonoid content (ideally 150 mg/day standardized to neoeriocitrin, naringin, and neohesperidin) and third-party testing for identity and potency.

The bergamot supplement market ranges from clinical-grade standardized extracts to low-quality products that may contain little active flavonoid content. Here is what to evaluate on the label:

Standardization to flavonoid content. The clinical trials used an extract standardized to about 40% total flavonoids, so 375 mg supplies 150 mg of flavonoids (Yu et al., 2026). A 375 mg dose of this extract delivers 150 mg of flavonoids, the validated clinical dose. Products should specify their flavonoid content per serving. Products listing only "bergamot extract 500 mg" without flavonoid standardization provide no assurance of potency.

Source specification. The extract should come from Citrus bergamia juice or albedo (inner peel), not from the aromatic peel essential oil. Essential oil contains bergapten and other furanocoumarins that are phototoxic when applied to skin, and the volatile terpene compounds in essential oil have no demonstrated cholesterol-lowering activity. Some products confusingly combine the words "bergamot" and "extract" without specifying whether the source is juice, peel, or essential oil.

Third-party testing — As with any supplement, look for certificates of analysis (COA) from independent laboratories verifying identity (is it really bergamot?), potency (does it contain the claimed flavonoid amount?), and purity (heavy metals, pesticide residues, microbial contamination). NSF, USP, or ConsumerLab certification provides additional assurance.

Combination products. Some supplements combine bergamot with other cholesterol-supporting ingredients (plant sterols, artichoke extract, red yeast rice). While combination approaches can be effective, they make it impossible to attribute any observed benefit to bergamot specifically. If you want to know whether bergamot works for you individually, start with a standalone bergamot extract before adding other ingredients.

Bergamot vs. Other Natural Cholesterol Approaches

Bergamot lowered LDL by 7% to 12% in its placebo-controlled trials (Spina et al., 2024) (Yu et al., 2026). Red yeast rice works like a low-dose statin, plant sterols block cholesterol absorption and soluble fiber binds bile acids. Combining approaches sounds logical, but a 2025 trial of a blend containing bergamot and plant sterols found no LDL benefit (Stonehouse et al., 2025).

Bergamot vs. red yeast rice. Red yeast rice contains monacolin K, the same molecule as the prescription drug lovastatin, so it behaves like a low-dose statin, with the same muscle and liver cautions. Product potency also varies widely. Bergamot works more weakly but is not a statin.

Bergamot vs. plant sterols. Plant sterols act on a different step: they block cholesterol absorption in the gut. In theory the two mechanisms could add up, but the one placebo-controlled trial of a blend containing both found no LDL reduction (Stonehouse et al., 2025).

Bergamot vs. soluble fiber. Psyllium and oat beta-glucan bind bile acids, so the liver uses more cholesterol to replace them. Fiber also helps digestion and post-meal glucose, which bergamot does not.

Bergamot and Weight Management

AMPK activation could in theory favor fat burning, but the controlled bergamot trials found no change in body weight over four months (Spina et al., 2024) (Yu et al., 2026). Bergamot should not be expected to cause weight loss.

AMPK activation in adipose tissue suppresses lipogenesis (the conversion of carbohydrates to stored fat) and stimulates lipolysis (the breakdown of stored triglycerides into free fatty acids for energy use). In the liver, AMPK reduces de novo lipogenesis and enhances fatty acid oxidation. These metabolic shifts are consistent with improved body composition over time, though the effect is gradual and modest compared to dietary and exercise interventions.

In both placebo-controlled trials, weight was tracked as a safety outcome and did not change (Spina et al., 2024) (Yu et al., 2026).

The mechanistic link between cholesterol metabolism and weight management through AMPK is well-established in pharmacology, metformin, the first-line diabetes drug that activates AMPK, is frequently associated with modest weight loss as a secondary benefit. Bergamot's AMPK activation, while weaker than metformin's, operates through a similar pathway and may produce analogous secondary body composition effects.

Bergamot is not marketed or validated as a weight-loss supplement. Its role is lipid support, ideally alongside diet and exercise.

Long-Term Safety and Duration of Use

The longest published placebo-controlled bergamot trials lasted four months and found no changes in liver or kidney markers, weight or blood pressure (Spina et al., 2024) (Yu et al., 2026). Data beyond that are lacking, so long-term users should recheck lipids and liver tests periodically.

Four months is the longest duration of controlled bergamot supplementation in published RCTs. During this period, no clinically significant changes in liver function (ALT, AST, GGT), kidney function (creatinine, BUN), hematological parameters, or body weight were observed in either the bergamot or placebo groups. This safety profile is reassuring for medium-term use but does not address potential issues with years-long supplementation.

From a mechanistic standpoint, there is no biological reason to expect cumulative toxicity from bergamot polyphenols. Unlike fat-soluble compounds that can accumulate in tissues (vitamin A, vitamin D), flavonoids are water-soluble metabolites that are conjugated in the liver and excreted through bile and urine within hours of absorption. There is no tissue accumulation pathway that would create a dose-dependent toxicity risk over time.

The CYP3A4 inhibition concern is duration-independent, if bergamot is going to interact with a CYP3A4-metabolized medication, it will do so regardless of whether you have been taking bergamot for one month or one year. The interaction is based on concurrent enzyme inhibition, not cumulative exposure.

Practical recommendation: if you plan to use bergamot long-term (>6 months), periodic lipid panel monitoring (every 3–6 months) is good practice, not because of safety concerns, but to confirm ongoing efficacy and adjust your strategy if cholesterol levels change. Liver function monitoring at the same intervals adds minimal cost and provides reassurance, particularly for people also taking statin medications or with pre-existing liver conditions.

Does citrus bergamot really lower cholesterol?

Yes, two placebo-controlled randomized trials confirm that standardized bergamot flavonoids at 150 mg/day significantly reduce total cholesterol (7–9%) and LDL cholesterol (7–12%) over four months. The effect is consistent across Caucasian and Asian populations. These reductions are more modest than statin therapy but are clinically meaningful for individuals with mildly elevated cholesterol (Spina et al., 2024) (Yu et al., 2026).

How long does bergamot take to lower cholesterol?

In clinical trials, measurable lipid changes appeared at the two-month mark and reached their maximum effect at four months. A single month of supplementation is generally insufficient to assess whether bergamot is working for a given individual. Plan to take it consistently for at least three to four months before evaluating results with follow-up blood work.

Can you take bergamot with statins?

One open-label study found that adding 1,000 mg/day of bergamot polyphenol fraction to 10 mg rosuvastatin lowered LDL more than rosuvastatin alone (Gliozzi et al., 2013). Because bergamot peel compounds can inhibit CYP3A4, which metabolizes atorvastatin and simvastatin, talk with your prescriber or pharmacist first.

What is the best dose of citrus bergamot for cholesterol?

The most rigorously validated dose is 150 mg/day of standardized flavonoids (approximately 375 mg of extract standardized to 40% flavonoids). This was the dose used in both the 2024 and 2026 double-blind RCTs. Some supplements provide 500–1,000 mg of less standardized extract, which may deliver comparable or higher flavonoid amounts but lacks the same level of controlled trial support (Yu et al., 2026).

Is citrus bergamot the same as bergamot essential oil?

No. Bergamot essential oil is pressed from the fruit's peel and used in aromatherapy and flavoring (Earl Grey tea). The supplement form is an extract from the juice or albedo (inner peel) standardized for polyphenolic flavonoid content. The biological activities relevant to cholesterol management come from the flavonoid fraction, not the volatile aromatic compounds in the essential oil. Do not ingest bergamot essential oil as a cholesterol supplement, it is not the same product.